Clinical Trial: A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer

U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07081555) titled 'A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer' on June 23.

Brief Summary: This is a FiH phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of [177Lu]Lu-ABY-271 in subjects with HER2 positive metastatic breast cancer.

Study Start Date: Aug. 01

Study Type: INTERVENTIONAL

Condition: Metastatic Breast Cancer HER2 + Breast Cancer

Intervention: DRUG: [177Lu]Lu-ABY-271

A single infusion of [177Lu]Lu-ABY-271

Recruitment Status: RECRUITING

Sponsor: Affibody

Disclaimer: Curated by HT Syndication....